Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.51 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losoxantrone SCHEMBL61319 | 1.00 | TOP2A (1.00) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL29409658 | 0.99 | TOP2A (0.98) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL6685621 | 0.99 | TOP2A (0.98) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL5170 | 0.98 | TOP2A (0.96) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10800466 | 0.94 | TOP2A (0.90) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL22877226 | 0.93 | TOP2A (0.87) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL18689529 | 0.93 | TOP2A (0.87) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10805434 | 0.92 | TOP2A (0.86) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10801795 | 0.89 | TOP2A (0.79) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10803842 | 0.88 | TOP2A (0.79) | TOP2AMEN1USP2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541414-B1 | CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI PHARMA INC (TW) | 2024-08-28 | — | — | EP | claimed |
| EP-3380124-B1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES INC (KR) | 2024-04-03 | — | — | EP | claimed |
| EP-3484496-B1 | METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES | UNIV SOUTHERN CALIFORNIA (US) | 2023-12-27 | — | — | EP | claimed |
| CN-112839649-B | CXCR4 inhibitor compositions and methods of making and using the same | X4 制药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250326745-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250299826-A1 | OPTIMAL TUMOR MICROENVIRONMENT NORMALIZATION THERAPY | UNIV CONNECTICUT (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4590400-A1 | NOVEL BINDING MOLECULES BINDING TO L1CAM | Elthera AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| CN-113521300-B | Antibody-drug conjugates comprising anti-human ROR1 antibodies and uses thereof | 基石药业（苏州）有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-112566937-B | Antibodies specific for CD3 and uses thereof | 辉瑞公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120051456-A | Substituted pyridone GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4189121-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4185568-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 | The University of Rochester (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116173036-A | E Mi Litong for glioma | 昂克希尔迪克斯有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116133692-A | Methods of treating mutant lymphomas | 凯麦拉医疗公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4139289-A1 | INHIBITORS OF HUMAN EPIDIDYMUS PROTEIN 4 | University of Rochester (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4096657-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022212894-A1 | METHODS FOR INHIBITING RAS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022031749-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022020661-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 | THE UNIVERSITY OF ROCHESTER (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326745-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PDPK1 | TOP2A 1189/4885MEN1 4234/4885USP2 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.